The objective of this study was to investigate whether vascular endothelial growth factor (VEGF) secreted by mesenchymal stem cells (MSC) improves myocardial survival and the engraftment of implanted MSC in infarcted hearts and promotes recruitment of stem cells through paracrine release of myocardial stromal cell-derived factor-1a (SDF-1a).
Methods and results

VEGF-expressing MSC (
VEGF MSC)-conditioned medium enhanced SDF-1a expression in heart slices and H9C2 cardiomyoblast cells via VEGF and the vascular endothelial growth factor receptor (VEGFR). The VEGF MSC-conditioned medium markedly promoted cardiac stem cell (CSC) migration at least in part via the SDF-1a/CXCR4 pathway and involved binding to VEGFR-1 and VEGFR-3. In vivo, VEGF MSC-stimulated SDF-1a expression in infarcted hearts resulted in massive mobilization and homing of bone marrow stem cells and CSC. Moreover, VEGF-induced SDF-1a guided the exogenously introduced CSC in the atrioventricular groove to migrate to the infarcted area, leading to a reduction in infarct size. Functional studies showed that VEGF MSC transplantation stimulated extensive angiomyogenesis in infarcted hearts as indicated by the expression of cardiac troponin T, CD31, and von Willebrand factor and improved the left ventricular performance, whereas blockade of SDF-1a or its receptor by RNAi or antagonist significantly diminished the beneficial effects of VEGF MSC.
Conclusion
Exogenously expressed VEGF promotes myocardial repair at least in part through SDF-1a/CXCR4-mediated recruitment of CSC.
Introduction
Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are crucial regulators of the growth, development, and differentiation of heart and blood vessels. 1 The therapeutic effect of VEGF is signified by the improvement of heart structure and function. 2, 3 VEGF gene delivery together with other growth factors and cell therapy (a part of the multimodal therapy approach) has been shown to promote the survival, engraftment, and differentiation of donor cells. 4, 5 The role of VEGF in engaging cardiac stem cells (CSCs) during the cardiac repair process, however, remains to be determined. Mesenchymal stem cells (MSC) are multipotential progenitor cells secreting a plethora of angiogenic and mitogenic cytokines and growth factors in normoxic culture condition; the secretion of these factors is increased significantly in response to anoxia. 6 Secretion of paracrine factors by other cell types, such as endothelial progenitor cells and cardiomyocytes (CMs), has also been reported. 7, 8 The expression of these cytokines provides an alternative and/or supportive mechanism for cell transplantation in tissue repair. 9 The paracrine pathway in CMs is important to maintain normal cardiac function due to VEGF release. 8 However, the mechanisms underlying the alteration of paracrine action in CMs after MSC transplantation are still unknown. We hypothesize that MSC play a pivotal role in recruiting CSC to the injured heart via the release of CM-derived SDF-1a, a potent chemoattractant of stem cells.
Methods
The present study was conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health. All animal protocols were approved by the Institutional Animal Care and Use Committee of Hubei University of Medicine.
Western blot and ELISA
Western blot was carried out with rabbit polyclonal antibody raised against SDF-1a (Santa Cruz) and mouse polyclonal antibody raised against VEGF (Santa Cruz) to identify the protein expression of VEGF and SDF-1a.
Rat left ventricles (LVs) were used for comparison among all groups 7 days after treatment. These samples were homogenized on ice in RIPA buffer containing protease inhibitors. Fifty micrograms of proteins was resolved in 12% SDS -PAGE gel and transferred onto a nitrocellulose membrane (Millipore). After being blocked with 5% non-fat milk, the membrane was incubated with primary antibody (1:1000 of dilution) for 90 min followed by incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies (anti-rabbit IgG and anti-mouse IgG, Santa Cruz). Protein expression was visualized by enhanced chemiluminescence reaction (Amersham Pharmacia Biotech) and measured by densitometry. Cardiac tissue and serum contents of hVEGF, rVEGF (Neobioscience, China), rSDF-1a (Ever System Biology Laboratory, Inc., USA), and hSDF-1a (R&D Systems, Minneapolis, MN, USA) were quantitatively measured by ELISA. 10 
Immunostaining
Heart tissues were fixed in 4% paraformaldehyde and embedded in optimum cutting temperature compound (Fisher Scientific). Serial transverse sections (5 mm) were cut across the longitude axis of the heart and mounted on slides. After a brief wash in phosphate-buffered saline (PBS), heart sections were incubated in a blocking buffer [PBS containing 1% foetal calf serum (FCS) and 0.1% Triton X-100] at room temperature for 1 h. Incubations in antibodies (diluted 1:250 in blocking buffer) were carried out at 48C overnight for primary antibodies, and room temperature for 2 h for secondary antibodies. The primary antibodies used were: mouse anti-rat CD31 (Abcam), rabbit anti-rat von Willebrand factor (VWF, Santa Cruz), rabbit anti-c-kit (Santa Cruz), rabbit anti-rat MDR1 (Santa Cruz), mouse anti-cardiac troponin T (cTnt, NeoMarkers), mouse anti-Flk-1 (Santa Cruz), goat anti-Flt-1 (Santa Cruz), and rabbit anti-rat CXCR4 (Santa Cruz). The secondary antibodies were TRITCconjugated anti-rabbit IgG, TRITC-conjugated anti-mouse IgG, FITC-conjugated anti-rabbit IgG, FITC-conjugated anti-mouse IgG, and FITC-conjugated anti-goat IgG (Santa Cruz). 10 
Characterization of hVEGF165-modified human MSC
Bone marrow-derived MSC were isolated and cultured as described previously. 11 Control (Ad-LacZ) and human VEGF165 (Ad-VEGF) adenoviral vector have been reported in our previous studies. 10 The replicationdeficient vectors were propagated in 293 cells cultured in DMEM supplemented with 15% foetal calf serum (FCS, Hyclone, USA). MSC were infected with Ad-LacZ or Ad-VEGF at a multiplicity of infection of 100 for 2 days to produce MSC expressing LacZ ( LacZ MSC) or VEGF165 ( VEGF MSC). MSC and supernatants were collected for examining the transduction efficiency and VEGF secretion, respectively, by ELISA and western blotting (see Supplementary material online, Data 1).
Isolation and culture of c-kit 1 cells from rat hearts
CSCs were isolated from the hearts of 3-day-old Sprague-Dawley (SD) rats by a method described previously. 10 Briefly, hearts were removed under aseptic conditions from rats that had been overdosed with sodium pentobarbital. Isolated myocardial tissue was cut into 1 -2 mm 3 pieces and washed with Ca 2+ and Mg 2+ -free PBS to remove blood.
Heart pieces were then digested with 0.2% trypsin (Invitrogen) and 0.1% collagenase IV (Sigma) at 378C for three times (5 min each digestion). At the end of enzymatic digestion, heart tissue was minced. Cell suspension was collected and filtered through a 0.22 mm filter (Becton Dickson). Cells were then incubated with a rabbit anti-c-kit antibody (Santa Cruz) and separated using sheep anti-rabbit immunomagnetic microbeads (Miltenyi Biotec 
Cell labelling
For transplantation studies, MSC were labelled with PKH26 cell tracker dye using a PKH26 Red Fluorescent Cell Linker Kit (Sigma) according to the manufacturer's instructions. The efficiency of PKH26 cell labelling was evaluated by flow cytometry (see Supplementary material online, Data 3).
Myocardial infarction and cell implantation
Myocardial infarction (MI) was achieved by ligation of the left anterior descending coronary artery (LAD) as previously described. 10 Briefly, SD rats (280 -300 g) were anaesthetized with ketamine (50 mg/kg, ip) and xylazine (10 mg/kg, ip). Tracheal ventilation with room air was carried out by using a Colombus ventilator (HX-300, Taimeng
Stem cell mobilization in the infarcted heart Instruments, China). Following left lateral thoracotomy at the fourth intercostal space, the LAD was ligated. Before chest closure, infarction was confirmed by observation of injury demarcation with blanching of the myocardium as well as electrocardiography. Rats were grouped randomly. One week after MI induction, the rat thorax was reopened, and suspensions of LacZ 
MSC or
VEGF MSC in serum-free medium (5 × 10 6 in 0.2 mL)
were injected with a 30-gauge tuberculin syringe into four sites (0.05 mL per site) for each MI heart in the implantation groups. Two injection sites were in the myocardium bordering the ischaemic area, and two within the ischaemic area. Vehicle (H 2 O) or AMD3100 (AMD) was continuously injected each per day for 6 days (1 mg/kg, ip) in VEGF MSC (VEGF), LacZ MSC (LacZ), and control (Ctrl) groups 1 day after cell implantation. Adenovirus expressing control (shCtrl) or SDF-1a shRNA (shSDF) was simultaneously injected with VEGF MSC implantation (see Supplementary material online, Data 4). In sham-operation group, rats underwent identical surgery but without ligation of the coronary artery. Penicillin (150 000 U/mL, iv) was given before each procedure. Buprenorphine hydrochloride (0.05 mg/kg, sc) was administered twice a day for the first 48 h after the procedure.
In vivo CSC migration assay with implantation of VEGF MSC
For intramyocardial implantation, cultured CSC were labelled with PKH26 following the manufacturer's instructions. 2 × 10 5 PKH26-labelled CSC at a volume of 50 mL were injected into the myocardium at the atrioventricular (AV) groove of infarcted hearts with implantation of VEGF MSC. In order to determine whether VEGF induces CSC migration through SDF1a/CXCR4, we used AMD3100 (10 mg/mL) to block CXCR4 activity prior to CSC injection. shSDF was used to confirm the specificity of AMD3100 inhibition. shSDF and VEGF MSC were simultaneously injected into four sites as described already.
Measurement of angiomyogenesis
CM was produced following the protocol described in Supplementary material online, angiogenesis in vivo was determined by the expression of a mature endothelial cell marker, vwFVIII.
Measurement of haemodynamic parameters
Measurements of haemodynamic parameters, histological, and morphometric analysis of hearts were carried out 28 days after the treatments as previously described. 10 Rats were anaesthetized with pentobarbital sodium (60 mg/kg, ip). The carotid artery and femoral artery were isolated. Two catheters that were filled with heparinized (10 U/mL) saline solution and connected to a Statham pressure transducer (Gould, Saddle Brook, NJ, USA) were planted into the carotid artery and femoral arteries. The carotid arterial catheter was advanced into the LV to record ventricular pressure. The femoral artery catheter was inserted into an isolated femoral artery and used to monitor mean arterial pressure (BP) and heart rate. These haemodynamic parameters including left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), and rate of rise and fall of ventricular pressure (+dP/dt max and -dP/dt max ) were monitored simultaneously and recorded on both a thermal pen-writing recorder (RJG-4122, Nihon Kohden, Japan) and an FM magnetic tape recorder (RM-7000, Sony, Tokyo, Japan). The heart was rapidly removed after the measurements were taken (n ¼ 10). 10 
Statistical analyses
Data are given as mean + SD. Statistical significance between two groups was determined by paired or unpaired Student's t-test. Results for more than two experimental groups were evaluated by one-way ANOVA to specify differences between groups. P , 0.05 was considered as significant difference.
Results
Transplantation of VEGF MSC stimulated SDF-1a expression in infarcted myocardium
Immunostaining showed that SDF-1a expression in the infarcted areas and peri-infarction areas were highly expressed in VEGF MSCtransplanted hearts ( Figure 1A ). Quantitative analysis indicated that the expression of both VEGF and SDF-1a protein was significantly elevated in the (peri) infarcted areas ( Figure 1B Stem cell mobilization in the infarcted heart 60%, while VEGF-induced SDF-1a from the (peri) infarcted tissues accounted for 40% of the total SDF-1a expressed in the (peri) infarcted areas ( Figure 1D ). 
3.2.
VEGF MSC-conditioned medium induced CXCR4 expression and promoted CSC migration in vitro SDF-1a exerts biological activities through binding to its receptor CXCR4. To determine whether VEGF secreted from MSC induces CXCR4 expression in cardiac CSC, we isolated CSC from rat hearts (see Supplementary material online, Data 6). 10 Flow cytometric analysis showed that majority of c-kit + CSC expressed VEGF receptors Flt-1 and Flk-1 (Figure 2A and B) . Forty-one per cent of CSC expressed CXCR4 ( Figure 2C ). However, VEGF MSC-conditioned medium ( VEGF CM) significantly increased the number of CSC that expressed CXCR4 ( Figure 2D) . Importantly, as shown in Figure 2E -F, all three VEGF receptors appeared to be involved in VEGF-induced CXCR4 expression although VEGFR1 and VEGFR3 had a greater effect than VEGFR2. As shown in Figure 2G , the migratory response of CSC to VEGF CM was increased two-fold compared with control. All VEGFR inhibitors inhibited VEGF CM-mediated CSC migration, although VEGFR1 and VEGFR3 inhibitors had a greater effect than VEGFR2 inhibitor, consistent with their effect on CXCR4 expression. Importantly, the increased migration was blocked by CXCR4 antagonist AMD3100 ( Figure 2H ), suggesting that VEGF enhanced CSC migration at least in part through SDF-1a/CXCR4 pathway. However, a direct effect of VEGF on CSC migration via binding VEGFR-1 and VEGFR-3 cannot be excluded at this point. 
Transplanted VEGF MSC induced mobilization of cardiac stem cells through CXCR4 in infarcted myocardium
To determine whether VEGF secreted from MSC is able to stimulate the mobilization of CSC in infarcted hearts, we implanted PKH26-labelled VEGF MSC in the infarcted areas, isolated the infarcted myocardium 7 days after the infarction, and detected the presence of CSC by immunostaining of stem cell markers c-kit and MDR1. A large number of c-Kit + and MDR1 + cells were observed in the VEGF MSCtransplanted myocardium ( Figure 3D and E). To determine whether VEGF stimulated CSC mobilization through SDF-1a/CXCR4 pathway, we used AMD3100 (AMD) to block CXCR4 activity, and found that the number of c-Kit + cells in the VEGF MSC engrafted areas was significantly reduced by AMD3100 treatment ( Figure 3C and F ) compared with the vehicle-treated infarcted hearts ( Figure 3B and D) . The dependence of VEGF in inducing CSC mobilization on SDF-1a/CXCR4 was confirmed by SDF-1a shRNA knockdown assay ( Figure 3H ). The reduction in c-kit + and MDR1 + cells by AMD3100 and SDF-1a shRNA clearly demonstrated that VEGF MSC stimulated CSC mobilization through SDF1a/CXCR4 pathway ( Figure 3I and J ).
The stem cells present in infarcted myocardium were further confirmed by RT-PCR of other stem cell markers CD31 and CD34 (see Supplementary material online, Data 7). 
VEGF MSC stimulated the migration of exogenously-introduced CSC in infarcted hearts
To confirm the role of VEGF in inducing CSC mobilization in infarcted heart, we labelled c-kit + cells isolated from rat hearts with PKH26.
The cells incubated with or without AMD3100 were implanted in the AV groove of infarcted hearts. The VEGF MSC were simultaneously implanted into the infarcted and peri-infarcted areas. We found that PKH26-labelled CSC migrated to the peri-infarction area ( Figure 4A and B). VEGF MSC implantation significantly increased the numbers of migrated CSC (Figure 4C and D) . However, AMD3100 ( Figure 4E and F ) and shSDF-1 ( Figure 4G and H ) inhibited VEGF MSC-induced (VEGF/AMD), or VEGF MSC transduced with adenovirus expressing SDF-1a shRNA (VEGF/shSDF) were implanted in the infarcted myocardium. The infarcted tissues were removed 28 days after the implantation. The angiogenesis was evaluated by measuring the microvessel density as shown by the expression of vwFVIII, a mature endothelial cell marker ( Figure 5D-H) . The number of blood vessels were counted for each treatment and analysed for their statistical difference ( Figure 5I ). We found that VEGF MSC significantly increased the blood vessel formation ( Figure 5F and I ). However, both AMD3100 and SDF-1a shRNA blocked the effect of VEGF MSC ( Figure 5G-I ). These data demonstrate that VEGF overexpressed from implanted MSC enhanced angiogenesis in infarcted myocardium. In addition, we found that transplanted MSC and mobilized cells can also be differentiated to cardiomyocytes (cTnt-positive, green) at the site of the cell graft in vivo (see Supplementary material online, Data 10), suggesting that the implantation of VEGF MSC has dual functions in cardiac repair after MI. Functional analysis showed that LV function, including LVSP, LVEDP, +dP/dt max, and -dP/dt max , was significantly improved in VEGF MSC-implanted hearts when compared with the control or 
Transplanted VEGF MSC reduced infarction size and improved cardiac function
Discussion
MSC therapy is currently a promising strategy in repairing MI. The beneficial effects of MSC implantation and mechanisms underlying MSC function, however, remain largely unknown. Modified MSC with overexpression of therapeutic genes of interest are likely to have better effects than unmodified MSC. 12 In this study, we found that VEGF-gene-modified MSC markedly reduced infarction size and improved the function of infarcted heart. The beneficial effects of VEGF MSC-implantation appeared to be mediated by the SDF-1a/ CXCR4 activation, which induced the mobilization and migration of CSC. MSC secrete numerous cytokines including VEGF, SDF-1, bFGF, IGF-1, and HGF. 12, 13 These paracrine factors, especially VEGF, are important for maintaining or improving normal cardiac function in MSC-mediated cardiac repair. 8, 14, 15 The functions of MSC are not only due to its potential to differentiate into cardiomyocytes and endothelial cells, 16, 17 but also depend on the paracrine effects, including enhanced survival of implanted MSC, 18 mobilization and migration of stem cells, 7,19 -21 which contribute to the overall repair of MI (see Supplementary material online, Data 13). Given the crucial role of SDF-1 in stem cell mobilization and retention, 22 SDF-1 was also produced in response to myocardial ischaemia. 23 Previous studies demonstrate that overexpression of SDF-1 in the heart provides a cue for stem cells to mobilize and home into the infarcted heart. Consequently, interactions between SDF-1 and CXCR4 contribute to ischaemic tissue repair. 23 -25 The present studies provide further support for the paracrine function of MSC in remodelling of infarcted myocardium. We found that VEGF-modified MSC, i.e. VEGF MSC- 29 The newly formed blood vessels and stem cells-differentiated cardiomyocytes may work together to restore the damaged myocardial tissues and improve the function of injured heart. Interestingly, CXCR4 antagonist AMD3100 not only inhibits cardiac function of VEGF MSC-implanted animals, but also reduces cardiac function of the control animals. AMD3100 effect on control animals is consistent with a recent report that long-term or chronic usage of AMD3100 has an anomalous effect on heart function. 30 AMD3100
appears to deteriorate cardiac function by inducing cardiac myocyte apoptosis. 30 In our study, AMD3100 reduces VEGF MSC-improved LV function with continuously intraperitoneal injections for 7 days after MI, suggesting that AMD3100 may have impaired heart function through both the induction of cardiac myocyte apoptosis and the blockade of CXCR4 receptor. The specific effect of SDF-1a/ CXCR4 pathway on cardiac function is further demonstrated by knocking down SDF-1a expression using shRNA ( Figure 6 ). Recent studies have shown that paracrine release of SDF-1a/ CXCR4 by Akt or IGF-1-modified MSC promotes myocardial repair. 18, 20, 31 IGF-1 has been reported to stimulate VEGF expression in endothelial cells. 32 Akt signalling appears to be critical for VEGF-induced postnatal angiogenesis. 33 We found that VEGF also stimulated Akt phosphorylation in MSC (see Supplementary material online, Data 14). Therefore, VEGF, IGF-1, Akt, and SDF-1a are likely to form an integrated system in the regulation of MSC functions in the cardiac repair after the infarction.
Clinical relevance
Although MSC are superior to angiogenic growth factors for improving myocardial performance with acute MI, 34 MSC therapy has limitations: age and other risk factors for cardiovascular diseases reduce MSC availability and limit its potential for differentiation and proliferation. 35 VEGF is a crucial paracrine factor in defining the age threshold in adult and neonatal stem cell function. 36 Expression of VEGF via VEGF MSC not only helps improve the function of transplanted MSC, including paracrine secretion of cytokines, survival, migration, and proliferation, but also contributes to the sustainable expression of VEGF gene. 35, 36 Since VEGF delivered in protein and gene form did not gain impressive results in clinical trials, 37 VEGF MSC implantation may be a potentially effective approach in enhancing cell therapy for cardiovascular diseases, especially for cardiac repair after MI. The underlying mechanism is that VEGF induces stem cells trafficking via activation of SDF-1/CXCR4 signalling pathway.
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